CSPC Pharmaceutical Group
Integrated pharmaceutical group developing small molecules and biologics across oncology, neurology, cardiovascular and infectious diseases.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · HER2-positive Breast Cancer
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric CancerPhase 3 · Recruiting · Gastric Cancer
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)Phase 3 · Recruiting · EGFR-mutated Locally Advanced or Metastatic NSCLC
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive DisorderPhase 3 · Recruiting · Major Depressive Disorder (MDD)
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaPhase 3 · Recruiting · Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Phase 3 · Recruiting · Heterozygous Familial Hypercholesterolemia (HeFH)
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/cspc-pharmaceutical-group/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.